FDA Calls for More Data on Dupilumab for CSU Indication ...Middle East

Medscape - News
In a letter, the FDA stated that additional efficacy data are required to support an approval for chronic spontaneous urticaria (CSU), according to the manufacturers of dupilumab. Medscape Medical News

Hence then, the article about fda calls for more data on dupilumab for csu indication was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Calls for More Data on Dupilumab for CSU Indication )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News


Latest News